If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi ® (glucagon) nasal powder
3mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Baqsimi™ (glucagon) nasal powder be used during pregnancy or lactation?
No clinical studies with Baqsimi have been performed in pregnant women or nursing mothers.
Use in Pregnancy and Lactation
No clinical studies with Baqsimi have been performed in pregnant women or nursing mothers.
Pregnancy
Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified
- a drug-associated risk of major birth defects
- miscarriage, or
- adverse maternal or fetal outcomes.1
Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation.1
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.1
Animal Data
In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m2) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality.1
Lactation
There is no information available on the
- presence of glucagon in human or animal milk
- effects of the drug on the breastfed infant, or
- effects of the drug on milk production.1
However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is, therefore, unlikely to cause harm to an exposed infant.1
Enclosed Prescribing Information
Reference
1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Date of Last Review: February 07, 2022